91561-99-8

Basic information

• Product Name: N,N-bis(2-chloroethyl)-p-methoxybenzylamine
• Synonyms: N,N-bis(2-chloroethyl)-p-methoxybenzylamine
• CAS NO: 91561-99-8
• Molecular Weight: 262.179
• Mol File: 91561-99-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: N,N-bis(2-chloroethyl)-p-methoxybenzylamine(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-bis(2-chloroethyl)-p-methoxybenzylamine(91561-99-8)
• EPA Substance Registry System: N,N-bis(2-chloroethyl)-p-methoxybenzylamine(91561-99-8)

Safety Data

• Hazardous Substances Data: 91561-99-8(Hazardous Substances Data)

Upstream product

• 111-42-2 2,2'-iminobis[ethanol] 
• 824-94-2 p-methoxybenzyl chloride 
• 2393-23-9 4-methoxy-benzylamine 
• 100-07-2 4-methoxy-benzoyl chloride 
• 500697-00-7 C₁₂H₁₅Cl₂NO₂ 
• 91554-59-5 2-[(2-hydroxy-ethyl)-(4-methoxy-benzyl)-amino]-ethanol 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 

Downstream Products

• 1403578-83-5 1-(4-methoxybenzyl)piperidine-4,4-dicarbonitrile 
• 1403578-86-8 3-(4-bromo-2-fluorophenyl)-9-(4-methoxybenzyl)-2,4,9-triazaspiro[5.5]undec-2-ene 
• 943123-13-5 1-(4-methoxybenzyl)-4-(3-nitrophenyl)piperazine 
• 212771-00-1 4-(4-methoxy-benzenesulfonyl)-1-(4-methoxy-benzyl)-piperidine-4-carboxylic acid ethyl ester 
• 212771-09-0 4-(4-n-butoxy-benzenesulfonyl)-1-(4-methoxy-benzyl)-piperidine-4-carboxylic acid ethyl ester 
• 287201-55-2 4-(4-but-2-ynyloxybenzenesulfonyl)-1-(4-methoxybenzyl)piperidine-4-carboxylic acid ethyl ester 

Relevant articles and documents

Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies

Malaria deaths have been decreasing over the last 10-15 years, with global mortality rates having fallen by 47% since 2000. While the World Health Organization (WHO) recommends the use of artemisinin-based combination therapies (ACTs) to combat malaria, the emergence of artemisinin resistant strains underscores the need to develop new antimalarial drugs. Recent in vivo efficacy improvements of the historical antimalarial ICI 56,780 have been reported, however, with the poor solubility and rapid development of resistance, this compound requires further optimization. A series of piperazine-containing 4(1H)-quinolones with greatly enhanced solubility were developed utilizing structure-activity relationship (SAR) and structure-property relationship (SPR) studies. Furthermore, promising compounds were chosen for an in vivo scouting assay to narrow selection for testing in an in vivo Thompson test. Finally, two piperazine-containing 4(1H)-quinolones were curative in the conventional Thompson test and also displayed in vivo activity against the liver stages of the parasite.

ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS / TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS

Compounds of the formula:useful in the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection.

N-hydroxy-2-(Alkyl,Aryl or Heteroaryl sulfanyl, sulfinyl or sulfonyl) 3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors

Matrix metalloproteinases (MMps) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-α converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-α from membrane bound TNF-α precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. The present invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF-α converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection. The compounds of this invention are represented by the formula where R1, R2, R3and R4are described herein.